Discover investment opportunities in Pharmaceutical Stocks List using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Pharmaceutical Stocks List using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Pharmaceutical Stocks List using our Smart AI Filter.
10 stocks found for "Pharmaceutical Stocks List"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.35 | ±28.9% | 6.7 | 5.29% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.49 | ±18.7% | 14.5 | 12.70% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.37 | ±19.7% | 14.7 | 3.18% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.45 | ±25.0% | 14.4 | 3.19% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What distinguishes Pfizer (PFE) from other pharmaceutical giants on this list?
A: Pfizer (PFE) is noted for its significant contributions to vaccines, particularly the COVID-19 vaccine developed with BioNTech. This exposure to vaccine development provides a unique growth avenue compared to peers focused mainly on traditional pharmaceuticals.
Q: Why might Merck (MRK) appeal to income-focused investors?
A: Merck (MRK) is often attractive to income investors due to its history of steady dividend payments and a robust payout ratio. This consistent income stream can be appealing to investors seeking stability.
Q: How does Johnson & Johnson (JNJ) maintain a competitive edge in the healthcare sector?
A: Johnson & Johnson (JNJ) benefits from a diversified product range spanning pharmaceuticals, medical devices, and consumer health products, reducing reliance on any single market segment.
Q: What are the growth prospects for Eli Lilly (LLY) in the coming decade?
A: Eli Lilly (LLY), with its strong pipeline of innovative drugs addressing diabetes, cancer, and autoimmune diseases, presents potential for growth. Investors track its R&D spending and regulatory approvals as key indicators.
Q: How does Gilead Sciences (GILD) perform during market downturns?
A: Gilead Sciences (GILD) may exhibit resilience in downturns due to its focus on antivirals and substantial revenue from stable HIV and hepatitis C treatments. This provides some insulation from broader market fluctuations.
Q: Are there specific ESG factors investors should consider with AbbVie (ABBV)?
A: Investors may consider AbbVie's (ABBV) focus on ethics in clinical trials and drug safety as key ESG factors. Its efforts in carbon footprint reduction in manufacturing also contribute to its ESG profile.
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read more